This article is sponsored by CMW Media, the premier public and media relations agency proudly serving the cannabis industry worldwide.
Next week, HempMeds Mexico President Raúl Elizalde will speak about cannabidiol (CBD) at the World Health Organization’s (WHO) International Drug Scheduling Convention in Geneva, Switzerland, on November 6th, 2017.
The invitation reflects the leadership role that organizations and governments throughout Central and South America have taken in adjusting their laws to allow the importation of CBD products to treat a variety of conditions including epilepsy and cancer. In contrast, some European nations like the United Kingdom have had a back and forth relationship with CBD products. In the U.S., meanwhile, fragmented state laws have seen the formation of CBD-product buyer’s clubs in some regions.
In the address, Elizalde hopes to educate world leaders about CBD, urging them to not consider CBD psychoactive and not schedule it as a drug. It’s an issue the long-time medical CBD advocate speaks to from personal experience.
After his daughter’s diagnosis with Lennox-Gastault Syndrome, a rare form of severe epilepsy, Elizalde founded the Por Grace Foundation to help other families affected by the disease. In addition to helping over 300 families, the Por Grace Foundation hosted a series of awareness events that eventually led to the first patients in Mexico being given special authorization to import medical cannabis products, setting the stage for more medical cannabis reform. The foundation has also helped to fund further scientific research into the efficacy of CBD products.